ReviewThe Lancet regional health. Southeast Asia2023
Ending TB in South-East Asia: flagship priority and response transformation.
Review in The Lancet regional health. Southeast Asia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Quality of life and multiple long-term conditions in Southeast Asia: a systematic review and meta-analysis.Nature communications · 2026Pooled it
- Review: missed tuberculosis cases in India: a systematic analysis of diagnostic, treatment, and reporting gaps.BMC health services research · 2025Pooled it
- BCG vaccination in Korea, Japan, and Taiwan: Current status and future perspectives.Human vaccines & immunotherapeutics · 2026Review
- Factors Influencing Tuberculosis Treatment Outcomes in Lalitpur District, Nepal: A Retrospective Cohort Study.Journal of epidemiology and global health · 2026Article
- Misdiagnosis and Coinfection of Localized Pulmonary Histoplasmosis with Pulmonary Tuberculosis: A Systematic Review of Published Cases.Journal of fungi (Basel, Switzerland) · 2026Review
- Risk Factors Associated With Tuberculosis Diagnostic Delay in the Jiangsu Province, China (2011-2021): Spatiotemporal Database Analysis Study.JMIR public health and surveillance · 2026Article
- Optimizing tuberculosis infection screening strategies for people living with HIV in Thailand: a cost-effectiveness analysis.BMC public health · 2025Article
- Spatial autocorrelation with environmental factors related to tuberculosis prevalence in Nepal, 2020-2023.Infectious diseases of poverty · 2025Article
- Association of clinical laboratory parameters with latent tuberculosis infection among healthcare workers of primary health centers-A cross-sectional observational study.PLOS global public health · 2025Article
- Decadal trends and regional disparities in tuberculosis burden: a comprehensive analysis of global, African, and Southeast Asian data from the GBD 1990-2021.Frontiers in public health · 2025Article
- Emerging Research Trends on Medication Adherence in Tuberculosis Treatment: A Bibliometric Study of Research Between 2015 and 2024 to Inform Future Research Trajectory.Patient preference and adherence · 2025Review
- Assessing the Role of Pradhan Mantri TB Mukt Bharat Abhiyaan in India's Fight against TB: A National-level Data-based Research Investigation.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineArticle
- Can interferon-inducible gene expression guide treatment? A prospective study in QuantiFERON-positive uveitis with undetermined cause.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 6 countries.
Funding
Abstract
Over the decades, the global tuberculosis (TB) response has evolved from sanatoria-based treatment to DOTS (Directly Observed Therapy Shortcourse) strategy and the more recent End TB Strategy. The WHO South-East Asia Region, which accounted for 45% of new TB patients and 50% of deaths globally in 2021, is pivotal to the global fight against TB. "Accelerate Efforts to End TB" by 2030 was adopted as a South-East Asia Regional Flagship Priority (RFP) in 2017. This article illustrates intensified and transformed approaches to address the disease burden following the adoption of RFP and new challenges that emerged during the COVID-19 pandemic. TB case notifications improved by 25% and treatment success rates improved by 6% between 2016 and 2019 due to interventions ranging from galvanising political commitments to empowering and engaging communities. Cumulative TB programme budget allocations in 2022 reached US$ 1.4 billion, about two and a half times the budget in 2016. An ambitious Regional Strategic Plan towards ending TB, 2021-2025, identifies priority interventions that will need investments of up to US$ 3 billion a year to fully implement them. Moving forward, countries in the Region need to leverage RFP and take up intensified, people-centred, holistic interventions for prevention, diagnosis, treatment and care of TB with commensurate investments and cross-ministerial and multi-sectoral coordination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.